Skip to main content
Erschienen in: Journal of Assisted Reproduction and Genetics 2-3/2009

01.03.2009 | ASSISTED REPRODUCTION

IVF/ICSI outcomes between cycles with luteal estradiol (E2) pre-treatment before GnRH antagonist protocol and standard long GnRH agonist protocol: a prospective and randomized study

verfasst von: Hong Ye, Guo-ning Huang, Ping-hong Zeng, Li Pei

Erschienen in: Journal of Assisted Reproduction and Genetics | Ausgabe 2-3/2009

Einloggen, um Zugang zu erhalten

Abstract

Objective

To study if luteal E2 pre-treatment before GnRH antagonist protocol improves IVF/ICSI outcomes compared with standard long GnRH agonist protocol.

Design

A prospective, randomized and controlled study.

Setting

ART center of a state public hospital

Patient(s)

Two hundred twenty infertile women underwent IVF/ICSI treatments.

Intervention(s)

Participants received oral Estradiol Valerate 4 mg/day preceding the IVF cycle from day 21 until day 2 of next cycle before GnRH antagonist protocol (E2 pre-treatment group n = 109) or received standard long GnRH agonist protocol as control group (n = 111).

Main outcome measure(s)

Number of oocytes collected, MII oocytes, fertilization, implantation, live birth and early pregnancy rate, and hormone profiles.

Result(s)

E2 pre-treatment exerted a significant suppressive effect on FSH but not LH secretion compared with basal FSH and LH levels. In E2 pre-treatment group serum LH level was significantly higher during COH and serum P was also significantly higher on the day of HCG injection compared with control group. Five patients from E2 pre-treatment group had elevated LH at all time (≥10 IU/L) and also a concomitantly high P (>1 ng/mL). Two of the five women achieved pregnancy but had early pregnancy loss. Overall, IVF/ICSI outcomes such as implantation, clinical pregnancy and live birth rates were similar between E2 pre-treatment and control groups.

Conclusion(s)

Luteal E2 pre-treatment before GnRH antagonist protocol significantly increases serum LH level and incidence rate of premature LH but no significant effect is observed on implantation, clinical pregnancy, live birth and early pregnancy loss rates compared with long GnRH agonist protocol. However, more studies in large numbers of cycles are needed to confirm that increased serum LH level by E2 pre-treatment during COH has no negative effect on the IVF/ICSI outcomes.
Literatur
3.
Zurück zum Zitat Devreker F, Pogonici E, De Maertelaer V, Revelard P, Vanden Bergh M, et al. Selection of good embryos for transfer depends on embryo cohort size: implication for the mila ovarian stimulation debate. Hum Reprod. 1999;14:3002–8. doi:10.1093/humrep/14.12.3002.PubMedCrossRef Devreker F, Pogonici E, De Maertelaer V, Revelard P, Vanden Bergh M, et al. Selection of good embryos for transfer depends on embryo cohort size: implication for the mila ovarian stimulation debate. Hum Reprod. 1999;14:3002–8. doi:10.​1093/​humrep/​14.​12.​3002.PubMedCrossRef
4.
Zurück zum Zitat Opsahl MS, Blauor KL, Black SH, Lincoln SR, Thorell L, Sherins RJ. The number of embryos available for transfer predicts successful pregnancy outcome in women over 39 years with normal ovarian hormonal reserve testing. J Assist Reprod Genet. 2001;18:551–6. doi:10.1023/A:1011906024170.PubMedCrossRef Opsahl MS, Blauor KL, Black SH, Lincoln SR, Thorell L, Sherins RJ. The number of embryos available for transfer predicts successful pregnancy outcome in women over 39 years with normal ovarian hormonal reserve testing. J Assist Reprod Genet. 2001;18:551–6. doi:10.​1023/​A:​1011906024170.PubMedCrossRef
5.
Zurück zum Zitat Fanchin R, Cunha-Filho JS, Schonauer LM, Kadoch IJ, Cohen-Bacri P, Frydman R. Coordination of early antral follicles by luteal estradiol administration provides a basis for alternative controlled ovarian hyperstimulation. Fertil Steril. 2003;79:316–21. doi:10.1016/S0015-0282(02)04574-0.PubMedCrossRef Fanchin R, Cunha-Filho JS, Schonauer LM, Kadoch IJ, Cohen-Bacri P, Frydman R. Coordination of early antral follicles by luteal estradiol administration provides a basis for alternative controlled ovarian hyperstimulation. Fertil Steril. 2003;79:316–21. doi:10.​1016/​S0015-0282(02)04574-0.PubMedCrossRef
6.
Zurück zum Zitat Fanchin R, Salomon L, Castelo-Branco A, Olivennes F, Frydman N, Frydman R. Luteal estradiol pre-treatment coordinates folliclar growth during controlled ovarian hyperstimulation with antagonist. Hum Reprod. 2003;18:2698–703. doi:10.1093/humrep/deg516.PubMedCrossRef Fanchin R, Salomon L, Castelo-Branco A, Olivennes F, Frydman N, Frydman R. Luteal estradiol pre-treatment coordinates folliclar growth during controlled ovarian hyperstimulation with antagonist. Hum Reprod. 2003;18:2698–703. doi:10.​1093/​humrep/​deg516.PubMedCrossRef
7.
Zurück zum Zitat Fanchin R, Cunha-Filho JS, Schonauer LM, Righini C, de Ziegler D, Frydman R. Luteal estradiol administration strengthens the relationship between day 3 follicle-stimulations hormone and inhibin B levels and ovarian follicular status. Fertil Steril. 2003;79:585–9. doi:10.1016/S0015-0282(02)04757-X.PubMedCrossRef Fanchin R, Cunha-Filho JS, Schonauer LM, Righini C, de Ziegler D, Frydman R. Luteal estradiol administration strengthens the relationship between day 3 follicle-stimulations hormone and inhibin B levels and ovarian follicular status. Fertil Steril. 2003;79:585–9. doi:10.​1016/​S0015-0282(02)04757-X.PubMedCrossRef
8.
Zurück zum Zitat Chun SY, Eisenhauer KM, Minami S, Billig H, Perlas E, Hsueh AJ. Hormonal regulation of apoptosis in early antral follicles: follicle-stimulating hormone sa a major survival factor. Endocrinology. 1996;137:1447–56. doi:10.1210/en.137.4.1447.PubMedCrossRef Chun SY, Eisenhauer KM, Minami S, Billig H, Perlas E, Hsueh AJ. Hormonal regulation of apoptosis in early antral follicles: follicle-stimulating hormone sa a major survival factor. Endocrinology. 1996;137:1447–56. doi:10.​1210/​en.​137.​4.​1447.PubMedCrossRef
9.
Zurück zum Zitat Klein NA, Battaglia DE, Fujimoto VY, Davis GS, Bremner WJ, Soules MR. Reproductive aging: accelerated ovarian follicular development associated with a monotropic follicle-stimulating hormone rise in normal older women. J Clin Endocrinol Metab. 1996;81:1038–45. doi:10.1210/jc.81.3.1038.PubMedCrossRef Klein NA, Battaglia DE, Fujimoto VY, Davis GS, Bremner WJ, Soules MR. Reproductive aging: accelerated ovarian follicular development associated with a monotropic follicle-stimulating hormone rise in normal older women. J Clin Endocrinol Metab. 1996;81:1038–45. doi:10.​1210/​jc.​81.​3.​1038.PubMedCrossRef
10.
Zurück zum Zitat Hillier SG, Van den Boogaard AM, Reichert LE Jr, Van Hall EV. Intraovarian sex steroia hormme interaction and the regulation of follicular maturation: aromatization of androgens by human granulose cells in vitro. J Clin Endocrinol Metab. 1980;50(4):640–7.PubMedCrossRef Hillier SG, Van den Boogaard AM, Reichert LE Jr, Van Hall EV. Intraovarian sex steroia hormme interaction and the regulation of follicular maturation: aromatization of androgens by human granulose cells in vitro. J Clin Endocrinol Metab. 1980;50(4):640–7.PubMedCrossRef
11.
Zurück zum Zitat Durnerin-Cedrin I, Bstandig B, Parneix L, et al. Effects of oral comfraceptive, synthetic progestogen or natural estrogen pre-treatments on the hormonal profile and the antral follicle cohort before GnRH antagonist protocol. Hum Reprod. 2007;22:109–16. doi:10.1093/humrep/del340.CrossRef Durnerin-Cedrin I, Bstandig B, Parneix L, et al. Effects of oral comfraceptive, synthetic progestogen or natural estrogen pre-treatments on the hormonal profile and the antral follicle cohort before GnRH antagonist protocol. Hum Reprod. 2007;22:109–16. doi:10.​1093/​humrep/​del340.CrossRef
12.
Zurück zum Zitat Laholu N, Chabbert-Buffer N, Christin-Maitre S, Le Nestour E, Roger M, Bouchard P. Main inhibitor of follicle stimulating hormone in the luteal-follicular transition: inhibin A, Destradios, or inhibin B? Hum Reprod. 1999;14:1190–3. doi:10.1093/humrep/14.5.1190.CrossRef Laholu N, Chabbert-Buffer N, Christin-Maitre S, Le Nestour E, Roger M, Bouchard P. Main inhibitor of follicle stimulating hormone in the luteal-follicular transition: inhibin A, Destradios, or inhibin B? Hum Reprod. 1999;14:1190–3. doi:10.​1093/​humrep/​14.​5.​1190.CrossRef
13.
Zurück zum Zitat Borm G, Mannaerts B. Treatment with the gonadotrophin-releasing hormone antagonist ganirelix in women undergoing ovarian stimulation with recombinant follicle stimulating hormone in effective, safe and convenient: results of a controlled, randomize, multi-centre trial. The European Orgalutran Study Group. Hum Reprod. 2000;15:1490–8. doi:10.1093/humrep/15.7.1490.PubMedCrossRef Borm G, Mannaerts B. Treatment with the gonadotrophin-releasing hormone antagonist ganirelix in women undergoing ovarian stimulation with recombinant follicle stimulating hormone in effective, safe and convenient: results of a controlled, randomize, multi-centre trial. The European Orgalutran Study Group. Hum Reprod. 2000;15:1490–8. doi:10.​1093/​humrep/​15.​7.​1490.PubMedCrossRef
14.
Zurück zum Zitat Al-Inany H, Aboulghar M. GnRH antagonist in assisted reproduction: a Cochrane review. Hum Reprod. 2002;7:874–85.CrossRef Al-Inany H, Aboulghar M. GnRH antagonist in assisted reproduction: a Cochrane review. Hum Reprod. 2002;7:874–85.CrossRef
15.
Zurück zum Zitat Huime JAF, van Loenen ACD, Schats R, McDonnell J, Hompes PGA, Schoemaker J, et al. Dose-finding study of daily GnRH antagonist for the prevention of premature LHsurges in IVF/ICSI patients: optimal changes in LH and progesterone for clinical pregnancy. Hum Reprod. 2005;20:359–67. Huime JAF, van Loenen ACD, Schats R, McDonnell J, Hompes PGA, Schoemaker J, et al. Dose-finding study of daily GnRH antagonist for the prevention of premature LHsurges in IVF/ICSI patients: optimal changes in LH and progesterone for clinical pregnancy. Hum Reprod. 2005;20:359–67.
16.
Zurück zum Zitat Kolibianakis EM, Zikopoulous K, Schiettecatte J, Smita J, Tournaye H, Camus M, et al. Profound LH suppression after GnRH antagonist administration is associated with a significantly higher ongoing pregnancy rate in IVF. Hum Reprod. 2004;19:2490–6. doi:10.1093/humrep/deh471.PubMedCrossRef Kolibianakis EM, Zikopoulous K, Schiettecatte J, Smita J, Tournaye H, Camus M, et al. Profound LH suppression after GnRH antagonist administration is associated with a significantly higher ongoing pregnancy rate in IVF. Hum Reprod. 2004;19:2490–6. doi:10.​1093/​humrep/​deh471.PubMedCrossRef
17.
Zurück zum Zitat Rombauts L, Healy D, Norman RJ. A comparative randomized trial to assess the impact of oral contraceptive pretreatment on follicular growth and hormone profiles in GnRH antagonist-treated patients. On behalf of the Orgalutran Scheduling Study Group. Hum Reprod. 2006;21:95–103. doi:10.1093/humrep/dei302. Rombauts L, Healy D, Norman RJ. A comparative randomized trial to assess the impact of oral contraceptive pretreatment on follicular growth and hormone profiles in GnRH antagonist-treated patients. On behalf of the Orgalutran Scheduling Study Group. Hum Reprod. 2006;21:95–103. doi:10.​1093/​humrep/​dei302.
18.
Zurück zum Zitat Kolibianakis EM, Albano C, Kahn J, Camus M, Tournaye H, Van Steirteghem AC, et al. Exposure to high levels of luteinizing hormone and estradiol in the early follicular phase of gonadotropin-releasing hormone antagonist cycles is hv+mcnkjjassociatoal with a reduced chance of pregnancy. Fertil Steril. 2003;79:873–80. doi:10.1016/S0015-0282(02)04920-8.PubMedCrossRef Kolibianakis EM, Albano C, Kahn J, Camus M, Tournaye H, Van Steirteghem AC, et al. Exposure to high levels of luteinizing hormone and estradiol in the early follicular phase of gonadotropin-releasing hormone antagonist cycles is hv+mcnkjjassociatoal with a reduced chance of pregnancy. Fertil Steril. 2003;79:873–80. doi:10.​1016/​S0015-0282(02)04920-8.PubMedCrossRef
Metadaten
Titel
IVF/ICSI outcomes between cycles with luteal estradiol (E2) pre-treatment before GnRH antagonist protocol and standard long GnRH agonist protocol: a prospective and randomized study
verfasst von
Hong Ye
Guo-ning Huang
Ping-hong Zeng
Li Pei
Publikationsdatum
01.03.2009
Verlag
Springer US
Erschienen in
Journal of Assisted Reproduction and Genetics / Ausgabe 2-3/2009
Print ISSN: 1058-0468
Elektronische ISSN: 1573-7330
DOI
https://doi.org/10.1007/s10815-009-9300-3

Weitere Artikel der Ausgabe 2-3/2009

Journal of Assisted Reproduction and Genetics 2-3/2009 Zur Ausgabe

Mehr Brustkrebs, aber weniger andere gynäkologische Tumoren mit Levonorgestrel-IUS

04.06.2024 Levonorgestrel Nachrichten

Unter Frauen, die ein Levonorgestrel-freisetzendes intrauterines System (IUS) verwenden, ist die Brustkrebsrate um 13% erhöht. Dafür kommt es deutlich seltener zu Endometrium-, Zervix- und Ovarialkarzinomen.

Prämenstruelle Beschwerden mit Suizidrisiko assoziiert

04.06.2024 Suizidalität Nachrichten

Manche Frauen, die regelmäßig psychische und körperliche Symptome vor ihrer Menstruation erleben, haben ein deutlich erhöhtes Suizidrisiko. Jüngere Frauen sind besonders gefährdet.

Alter der Mutter beeinflusst Risiko für kongenitale Anomalie

28.05.2024 Kinder- und Jugendgynäkologie Nachrichten

Welchen Einfluss das Alter ihrer Mutter auf das Risiko hat, dass Kinder mit nicht chromosomal bedingter Malformation zur Welt kommen, hat eine ungarische Studie untersucht. Sie zeigt: Nicht nur fortgeschrittenes Alter ist riskant.

Fehlerkultur in der Medizin – Offenheit zählt!

28.05.2024 Fehlerkultur Podcast

Darüber reden und aus Fehlern lernen, sollte das Motto in der Medizin lauten. Und zwar nicht nur im Sinne der Patientensicherheit. Eine negative Fehlerkultur kann auch die Behandelnden ernsthaft krank machen, warnt Prof. Dr. Reinhard Strametz. Ein Plädoyer und ein Leitfaden für den offenen Umgang mit kritischen Ereignissen in Medizin und Pflege.

Update Gynäkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert – ganz bequem per eMail.